IP Library Granted Patent US 10,253,297
Granted Patent B2
US 10,253,297 · App. 13/889,015 · Granted Apr 9, 2019

Stem cell aggregates and methods for making and using

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,253,297
App. No.
13/889,015
Granted
Apr 9, 2019
Kind
B2
Abstract

The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.

Claims (12)

1. A method comprising (1) disaggregating cells in an aggregate, the aggregate having been formed by exposing cells that are not embryonic stem cells, embryonic germ cells, or germ cells and can differentiate into cell types of at least two of the endodermal, ectodermal, mesodermal embryonic lineages, to conditions under which the cells aggregate, wherein the conditions comprise an oxygen concentration of about 1-10%, wherein the aggregate from which the disaggregated cells are derived does not originate from two-dimensional culture and (2) administering to a subject, in an amount and for a time sufficient to achieve a desired effect in the subject, the cells derived from disaggregating the aggregate of cells.

2. The method of claim 1 , wherein cells are aggregated by the hanging drop method or forced aggregation method.

3. The method of claim 1 , wherein the aggregation of the aggregate is carried out in cell culture.

4. The method of claim 1 , wherein cells in the aggregate and cells derived from the aggregate express one or more of Oct 3/4, telomerase, rex-1, rox-1, nanog, GATA6 and sox-2.

5. The method of claim 1 or 4 , wherein cells in the aggregate and cells derived from the aggregate can differentiate into cell types of all three of the endodermal, ectodermal and mesodermal embryonic lineages.

6. The method of claim 1 , wherein the aggregate contains about 10 cells to about 50,000 cells or more.

7. The method of claim 1 , wherein the aggregate contains about 1000 cells to about 5000 cells.

8. The method of claim 1 or 4 , wherein the non-embryonic stem, non-embryonic germ, non-germ cells are derived from bone marrow.

9. The method of claim 5 , wherein the non-embryonic stem, non-embryonic germ, non-germ cells are derived from bone marrow.

10. The method of claim 8 , wherein the non-embryonic stem, non-germ cells are human cells.

11. The method of claim 9 , wherein the non-embryonic stem, non-germ cells are human cells.

12. The method of claim 1 or 4 further comprising admixing the disaggregated cells with a pharmaceutically-acceptable vehicle for administration to a subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →